Skip to content
Home/Companies/Biotech/Amply
Amply

Amply

Biotech·United Kingdom·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns Amply?

Amply is a British Biotech company, currently owned by Clarendon Fund Managers since 2022.

Hand-verified · updated 2026-06-21

Open JSON · CC-BY
Clarendon Fund Managers
Investor
Clarendon Fund Managers
Co-Fund NI · 2012 · VC

Key facts

HQUnited Kingdom
SectorBiotech
StatusActive
Websiteamplydiscovery.com

More from Co-Fund NI

Other portfolio companies in the same fund.

GenoME Diagnostics
GenoME Diagnostics
Active
BiotechUK· 2023
Kinsetsu
Active
SaaSUK· 2023
Angoka
Angoka
Active
CybersecurityUK· 2022
Aramune Technologies
Aramune Technologies
Active
BiotechUK· 2022
CV6 Therapeutics
CV6 Therapeutics
Active
BiotechUK· 2022
Modern Democracy
Modern Democracy
Active
SaaSUK· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Amply?

Amply is currently owned by Clarendon Fund Managers, through Co-Fund NI, since 2022.

When did Clarendon Fund Managers acquire Amply?

Clarendon Fund Managers acquired Amply in 2022.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue